With the widespread clinical use of comparative genomic hybridization chromosomal microarray technology, several previously unidentified clinically significant submicroscopic chromosome abnormalities have been discovered. Specifically, there have been reports of clinically significant microduplications found in regions of known microdeletion syndromes. In general, these microduplications have distinct features from those described in the corresponding microdeletion syndromes. We present a 5 1 / 2 -year-old patient with normal growth, borderline normal IQ, borderline hypertelorism, and speech and language delay who was found to have a submicroscopic 2.3 Mb terminal duplication involving the two proposed WolfHirschhorn syndrome (WHS) critical regions at chromosome 4p16.3. This duplication was the result of a maternally inherited reciprocal translocation involving the breakpoints 4p16.3 and 17q25.3. Our patient's features are distinct from those described in WHS and are not as severe as those described in partial trisomy 4p. There are two other patients in the medical literature with 4p16.3 microduplications of similar size also involving the WHS critical regions. Our patient shows clinical overlap with these two patients, although overall her features are milder than what has been previously described. Our patient's features expand the knowledge of the clinical phenotype of a 4p16.3 microduplication and highlight the need for further information about it.
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INTRODUCTION
With the advent of comparative genomic hybridization (CGH) chromosomal microarray technology, several clinically significant submicroscopic duplications in regions known to cause microdeletion syndromes have been identified. The features of these microduplication syndromes are clinically distinct from the microdeletion syndromes that share the same regions. Some of these include duplication of 22q11.2, the region involved in Velocardiofacial syndrome [Portnoi, 2009] , duplication of 7q11.23, the region involved in Williams syndrome [Van der Aa et al., 2009] , and duplication of 17p11.2 (Potocki-Lupski syndrome), the region involved in Smith-Magenis syndrome [Potocki et al., 2007] .
We present a 5 1 / 2 -year-old female patient with a submicroscopic 2.3 Mb terminal duplication of 4p16.3. This duplication involves the two proposed critical regions for Wolf-Hirschhorn syndrome (WHS), which is a well-characterized microdeletion syndrome caused by a deletion of 4p16.3. The first critical region, called WHSCR1, is a 165 kb area approximately 2 Mb from the telomere of 4p and includes the genes WHSC1 and WHSC2 [Wright et al., 1997 [Wright et al., , 1999 Stec et al., 1998 ]. The second critical region, called WHSCR2, includes WHSC1 and LETM1 and is contiguous and telomeric to WHSCR1. It is estimated to be 300-600 kb in size positioned between 1.9 and 1.6-1.3 Mb from the telomere [Zollino et al., 2003] .
Our patient's clinical features are distinct from those described in WHS and are not as severe as those found in individuals with cytogenetically detectable partial trisomy 4p [Gonzalez et al., 1977; Patel et al., 1995; Battaglia et al., 2002] . This case provides further information regarding the clinical significance and variability of a microduplication of 4p16.3.
CLINICAL REPORT
Our patient was initially referred at age 4 years, 4 months for evaluation of a mild intention tremor, speech delay, and dysmorphic facial features. She was born to a 26-year-old, primagravida female. The pregnancy was uncomplicated and there were no teratogenic exposures. She was delivered at 40 weeks gestation by cesarean for breech presentation. Birth weight was 2.89 kg (10th centile); length was 47 cm (10th centile). Head circumference and APGARS were unknown. She was diagnosed with bilateral hip dysplasia and required a harness for 5 weeks. A cardiologist diagnosed her as having an innocent heart murmur. She also had a normal ophthalmology examination.
There were no concerns for her early developmental milestones. She reportedly sat at 5 months, took her first steps at 12 months, and spoke her first words at 9 months. There were concerns regarding her speech pronunciation at 18 months of age. She could speak two word phrases at approximately 2 1 / 2 -3 years of age. Her developmental assessment at 3 1 / 2 years of age showed delays in her communication skills as well as mild delays in her gross and fine motor skills. She had been evaluated by a neurologist for a mild intention tremor. Developmental delay was noted but no specific cause for the tremor was identified. Our physical examination at age 4 years, 4 months showed: weight 15.8 kg (50th centile); height 99.0 cm (25th centile), and head circumference 49.5 cm (just <50th centile). She had borderline hypertelorism with an intercanthal distance of 3.25 cm (90th centile). There were no other dysmorphic features ( Fig. 1 ). Neurologic examination was negative; we did not notice the intention tremor. Karyotype was normal female 46,XX.
The patient was seen for a follow-up visit at 5 1 / 2 years of age. In addition to the above, she had developed pubic hair at 5 years of age. An endocrine evaluation was normal. Her bone age was found to be between 7 years, 10 months and 8 years, 10 months which is advanced in comparison to her chronologic age of 5 years, 7 months at the time of the evaluation. She also had a reported history of polyuria/polydipsia and night-time intermittent urinary incontinence. Her serum electrolytes were normal. She had WPPSI-III performed at 5 1 / 2 years of age which showed a full scale IQ of 80; verbal IQ of 80; performance IQ of 88. She was found to have poor adaptive behavior, poor communication, and moderate-tosevere delays in receptive and expressive speech. On physical examination, weight was 20.2 kg (50th-75th centile); height was 105 cm (10th centile), and head circumference was 50.5 cm (50th centile). Her facial features were unchanged. Her breast development was at Tanner stage I. There was slight dark pubic hair over the labia majora. Her neurologic examination showed no abnormality.
The patient's younger sister presented to us at the same time as our patient at 5 months of age for an initial evaluation for failure to thrive. The sister's evaluation was unremarkable aside from the failure to thrive. The sister presented again at 21 months, at the same time as our patient, with failure to thrive and the additional findings of developmental delay and a new onset of seizures. At this follow-up visit, we drew the sister's blood for chromosomal microarray analysis.
Family history was remarkable for a 40-year-old maternal great aunt who reportedly has short stature, intellectual disability, and seizures of unknown etiology.
METHODOLOGY AND RESULTS Oligonucleotide aCGH
Oligonucleotide-based microarray analysis was performed using a 105K-feature whole-genome microarray (SignatureChip Oligo Solution Ò , designed by Signature Genomic Laboratories (Spokane, WA) and Agilent Technologies (Santa Clara, CA) and made by Agilent Technologies) as previously described [Ballif et al., 2008] . Our patient's sister was found to have the following result: arr 4p16. 3(35,881-2,297,002)x1,17q25.3(78,323,289-78,637,842) x3. This resulted in a terminal deletion at 4p16.3 which was approximately 2.3 Mb in size and a terminal duplication at 17q25.3 which was approximately 314.6 kb in size. The 4p16.3 deletion involves both WHSCR1 and WHSCR2 (Figs. 2 and 3 ).
Fluorescence In Situ Hybridization (FISH) Analysis
Metaphase FISH analysis was performed using BAC clones RP11-478C6 and RP11-46H21 to visualize the abnormalities as previously described [Traylor et al., 2009] . These results confirmed that the sister's abnormality was the result of an unbalanced translocation between 4p16.3 and 17q25.3. This abnormality, together with the sister's clinical features, confirmed a diagnosis of WHS in her. Following the sister's results, metaphase FISH analysis was performed on the mother and then subsequently on our patient. The mother's FISH results detected a balanced translocation between 4p16.3 and 17q25.3 (Fig. 4) . Our patient was detected as having the reciprocal version of the unbalanced translocation, namely a terminal duplication at 4p16.3 and a terminal deletion at 17q25.3 (Fig. 5) . Thus far, no other family members have been tested for the presence of this translocation. 
DISCUSSION
We present a case of a submicroscopic duplication of 4p16.3 involving the WHS critical regions. This case is clinically distinct from both WHS and the trisomy 4p syndrome. The classic clinical features of WHS include prenatal and postnatal growth retardation, intellectual disability, seizures, and distinctive dysmorphic facial features described as a ''Greek warrior helmet'' facies [Battaglia et al., 2008] . Our patient does not have any of these classic features and there is very little clinical overlap of her features with WHS.
Trisomy 4p is a distinct clinical entity that has been described in more than 75 cases. In general, patients are trisomic for at least the distal 2/3 of 4p. Clinical features include growth retardation, psychomotor retardation, cardiac anomalies, and renal anomalies. The dysmorphic features include a prominent glabella, bulbous nose with a flat nasal bridge, retrognathia, abnormal ears, and rocker bottom feet [Gonzalez et al., 1977; Patel et al., 1995] . There have been several patients with trisomy 4p described in the medical literature that have documented involvement of the WHS loci, however, almost all cases have been cytogenetically detectable duplications, and, therefore, larger than the duplication present in our case [Cotter et al., 2001; Tschernigg et al., 2002; GerardBlanluet et al., 2004; Takeno et al., 2004; Bartocci et al., 2008] . Our patient has none of the severe features described in these patients.
Thus far, there have been only two other cases in the medical literature with submicroscopic duplications of 4p involving the WHS critical regions. Rosell o et al. [2009] describe a 10-year-old boy who was found to have a 1.1 Mb duplication involving the WHS critical regions. However, he also had a 1.3 Mb distal deletion of 4p. It has been suggested that a deletion distal to the WHS critical regions may be responsible for seizures, developmental delay, and growth retardation seen in some patients with a ''mild'' WHS phenotype [South et al., 2008] . Therefore, his phenotype may not be solely explained by his duplication of 4p.16.3. However, there still is clinical overlap between our case and this patient including hypertelorism, normal height, and developmental delay most significant in speech (Table I) .
More recently, Hannes et al. [2010] presented a 15-month-old child with a 560 kb interstitial duplication of 4p16.3 also involving the WHS critical regions. He additionally was found to have an inversion between 4p16.3 and 4q22. His clinical features are much more significant than our patient and the patient presented by Rosell o et al. [2009] and include a hand malformation, hypotonia, glaucoma of the left eye, and development at a 5-month old level (Table I) . Given the severity of his features, it is possible that his inversion may be affecting his phenotype in some way, possibly by a gene disruption of some kind.
Our patient, in addition to the terminal duplication of 4p16.3, has a 314.6 kb deletion of 17q25.3. Thus far, there have not been any cases in the medical literature with a deletion of 17q25.3 of this size causing a clinically significant phenotype. In fact, there has been some evidence to suggest that a deletion of 17q25.3 is a benign copy number variant [Balikova et al., 2007] . There are only four genes in the 17q25.3 region. Tubulin-specific chaperone D (TBCD) has been found to be expressed in brain tissue [Nagase et al., 1999] . Zinc finger protein 750 (ZNF750) has been found to be expressed in several tissues including human keratinocytes but not in the brain [Birnbaum et al., 2006] . Beta 3N-acetyleglucosaminyltransferase (B3GNTL1) was isolated from fetal brain cDNA but was found to be expressed most significantly in the adult pancreas [Zheng et al., 2004] . And finally, Meteorin (METRNL) is thought to be involved in neurogenesis and in angiogenesis at the glialvascular interface [Nishino et al., 2004; Park et al., 2008] . Despite the fact that 3 of these 4 genes are expressed in the brain, there is no information indicating if haploinsufficiency of any of these genes is sufficient to cause a clinically significant phenotype. However, we cannot rule out the possibility that the deletion at 17q25.3 could be contributing to our patient's phenotype.
Our patient's case illustrates several important concepts. She presents with a relatively mild phenotype when compared to other individuals with a duplication of 4p16.3. Her mild phenotype suggests that there may be wide variability of the features associated with this duplication. Additionally, our case helps provide prognostic information regarding microduplications in general. Our patient's phenotype is milder than what has been described in WHS even in those cases involving small deletions of 4p16.3 <3.5 Mb . Therefore, our patient's case provides further evidence that, in general, microduplications are better tolerated than microdeletions of the same region. Additionally, our patient provides further evidence of the pathogenic nature of copy number changes in areas known to involve dosage-sensitive genes. It has been suggested that the same dosage-sensitive genes known to be pathogenic when haploinsufficient in microdeletion syndromes may cause different phenotypic consequences if they are over-expressed. Portnoi [2009] suggests that over-expression of TBX1 (a major gene associated with the Velocardiofacial/Digeorge syndrome phenotype) may be the cause of the 22q11.2 microduplication syndrome. Potocki et al. [2007] has proposed that the RAI1 gene (a gene thought to be causative in Smith-Magenis syndrome) may be responsible for the features of Potocki-Lupski syndrome when over-expressed. While our single case does not help us identify which of the genes in the WHS critical regions may be responsible for our patient's phenotype, it suggests that there may be genes in the region that are sensitive to overexpression.
In conclusion, our patient's case helps expand the understanding of the nature of pathogenic microduplications in general. Additionally, it provides evidence that a microduplication of 4p16.3 involving the WHS critical regions causes a clinically relevant phenotype, likely with extreme variability. It also highlights the need for further research on pathogenic microduplications involving dosage-sensitive genes in general and more specifically on the emerging phenotype associated with a microduplication of 4p16.3. 
